{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.2","upperLimit":"29.9","value":"19.3"}]}],"title":"Overall Response Rate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.3","upperLimit":"57.3","value":"45.6"}]}],"title":"Disease Control Rate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"description":"Central assessments of tumor response were performed by the Efficacy and Safety review Committee according to the Revised Response Criteria for Malignant Lymphoma developed in 2007 based on computed tomography (CT) and fluorodeoxyglucose-positron emission tomography (FDG-PET) findings. Overall Response Rate was defined as the percentage of participants who achieved Complete Response (CR, disappearance of all evidence of disease) or Partial Response (PR, regression of measurable disease and no new sites) as their best response. Disease Control Rate is defined as the percentage of participants who achieved CR, PR or Stable Disease (SD) as their best response.","dispersionType":"90% Confidence Interval","groups":[{"description":"SP-02L (darinaparsin for injection): Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days","id":"OG000","title":"SP-02L (Darinaparsin for Injection)"}],"paramType":"NUMBER","populationDescription":"Efficacy analysis set included patients who fulfilled eligibility criteria and who took a tumor response assessment at least one time after the administration of SP-02L (darinaparsin for injection).","reportingStatus":"POSTED","timeFrame":"Central assessments of tumor response were performed every 3 cycles, and/or at the end of treatment visit, during 6-cycle treatment period. The best response was determined during 6-cycle treatment period. Maximum duration of assessments was 5.3 months.","title":"Tumor Response (Central Assessment)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}